The present study examined whether (1) the cough associated with @entity1289 inhibitor therapy is attenuated by oral intake of @entity68 and anti-oxidants, and (2) @entity842 (NO) has any role in this attenuation. Of the 100 @entity1 under investigation, cough occurred in 28 of them with preponderance in females. All the 28 @entity1 were followed up for six weeks: the first two weeks were the observation period and the remaining four weeks the experimentation period. After the observation period, 11 @entity1 received a single oral dose of @entity20150 (200 mg), eight received @entity270 (200 mg, o.d.) and @entity620 (150 mg, o.d.) and nine were given placebo during the experimentation period. Cough scoring, serum NO and @entity1234 ( @entity1865 ) levels were determined during both the periods. While there were significant decreases in cough scores, NO and @entity1865 levels between these two periods in the @entity68 group, cough scores and @entity1865 level decreased significantly in the anti-oxidant group. None of these parameters changed in the control group. NO level was found to be increased significantly in @entity1 who developed cough (n = 28) compared with those who did not cough (n = 72). These results suggest that @entity68 supplementation suppresses cough in @entity1 on ACE-I therapy through its effect on NO generation.

Attenuation of @entity1289 inhibitor induced cough by XXXX supplementation: role of @entity842 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1289 :: ('1636', 'Gene') :: ['angiotensin converting enzyme'] @entity270 :: ('MESH:D014810', 'Chemical') :: ['vitamin E'] @entity620 :: ('MESH:D001205', 'Chemical') :: ['vitamin C'] @entity1234 :: ('MESH:D008315', 'Chemical') :: ['malondialdehyde'] @entity842 :: ('MESH:D009569', 'Chemical') :: ['nitric oxide'] @entity20150 :: ('MESH:C020748', 'Chemical') :: ['ferrous sulphate'] @entity1865 :: ('CHEBI:566274', 'Chemical') :: ['MDA'] @entity68 :: ('MESH:D007501', 'Chemical') :: ['iron']
@entity68 :: (MESH:D007501,Chemical) :: ['iron']
